These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 27886817)

  • 1. Antithrombotic Therapy to Reduce Ischemic Events in Acute Coronary Syndromes Patients Undergoing Percutaneous Coronary Intervention.
    Verheugt FW
    Interv Cardiol Clin; 2017 Jan; 6(1):131-140. PubMed ID: 27886817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic strategies in the catheterization laboratory for patients with acute coronary syndromes undergoing percutaneous coronary interventions: insights from the EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitalized in iTalian cardiac care units Registry.
    De Luca L; Musumeci G; Leonardi S; Gonzini L; Cavallini C; Calabrò P; Mauro C; Cacciavillani L; Savonitto S; De Servi S;
    J Cardiovasc Med (Hagerstown); 2017 Aug; 18(8):580-589. PubMed ID: 28639987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antithrombotic therapy of acute coronary syndromes].
    Hölschermann H
    Hamostaseologie; 2007 Dec; 27(5):319-25; quiz 326-7. PubMed ID: 18060240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is routine post-procedural anticoagulation warranted after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction? Insights from the HORIZONS-AMI trial.
    Madhavan MV; Généreux P; Kirtane AJ; Xu K; Witzenbichler B; Mehran R; Stone GW
    Eur Heart J Acute Cardiovasc Care; 2017 Oct; 6(7):650-658. PubMed ID: 26124455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.
    Gibson CM; Morrow DA; Murphy SA; Palabrica TM; Jennings LK; Stone PH; Lui HH; Bulle T; Lakkis N; Kovach R; Cohen DJ; Fish P; McCabe CH; Braunwald E;
    J Am Coll Cardiol; 2006 Jun; 47(12):2364-73. PubMed ID: 16781360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic therapy after percutaneous coronary intervention from the Japanese perspective.
    Saito Y; Kobayashi Y; Tanabe K; Ikari Y
    Cardiovasc Interv Ther; 2020 Jan; 35(1):19-29. PubMed ID: 31845096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
    Stone GW; Ware JH; Bertrand ME; Lincoff AM; Moses JW; Ohman EM; White HD; Feit F; Colombo A; McLaurin BT; Cox DA; Manoukian SV; Fahy M; Clayton TC; Mehran R; Pocock SJ;
    JAMA; 2007 Dec; 298(21):2497-506. PubMed ID: 18056903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost Effectiveness of Antiplatelet and Antithrombotic Therapy in the Setting of Acute Coronary Syndrome: Current Perspective and Literature Review.
    Fanari Z; Weiss S; Weintraub WS
    Am J Cardiovasc Drugs; 2015 Dec; 15(6):415-27. PubMed ID: 26068886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Harrington RA; Becker RC; Cannon CP; Gutterman D; Lincoff AM; Popma JJ; Steg G; Guyatt GH; Goodman SG
    Chest; 2008 Jun; 133(6 Suppl):670S-707S. PubMed ID: 18574276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    White HD; Ohman EM; Lincoff AM; Bertrand ME; Colombo A; McLaurin BT; Cox DA; Pocock SJ; Ware JA; Manoukian SV; Lansky AJ; Mehran R; Moses JW; Stone GW
    J Am Coll Cardiol; 2008 Sep; 52(10):807-14. PubMed ID: 18755342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoinvasive management of acute coronary syndrome: incorporating the 2007 ACC/AHA guidelines: the CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report--III.
    Cohen M; Diez JE; Levine GN; Ferguson JJ; Morrow DA; Rao SV; Zidar JP; ;
    J Invasive Cardiol; 2007 Dec; 19(12):525-38; quiz 539-40. PubMed ID: 18180524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study.
    De Luca L; Leonardi S; Cavallini C; Lucci D; Musumeci G; Caporale R; Abrignani MG; Lupi A; Rakar S; Gulizia MM; Bovenzi FM; De Servi S;
    Eur Heart J Acute Cardiovasc Care; 2015 Oct; 4(5):441-52. PubMed ID: 25414322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
    Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of antithrombotic agents during urgent percutaneous coronary intervention following thrombolytic therapy: A retrospective cohort study.
    Mallidi JR; Robinson P; Visintainer PF; Lotfi AS; Mulvey S; Giugliano GR
    Catheter Cardiovasc Interv; 2017 Nov; 90(6):898-904. PubMed ID: 28417608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of P2Y
    Tantry US; Navarese EP; Myat A; Gurbel PA
    Prog Cardiovasc Dis; 2018; 60(4-5):460-470. PubMed ID: 29339168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy.
    Kwa AT; Rogers JH
    J Interv Cardiol; 2008 Apr; 21(2):107-17. PubMed ID: 18248357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
    Tricoci P; Newby LK; Hasselblad V; Kong DF; Giugliano RP; White HD; Théroux P; Stone GW; Moliterno DJ; Van de Werf F; Armstrong PW; Prabhakaran D; Rasoul S; Bolognese L; Durand E; Braunwald E; Califf RM; Harrington RA
    Circ Cardiovasc Qual Outcomes; 2011 Jul; 4(4):448-58. PubMed ID: 21712522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes.
    Jennings LK; Saucedo JF
    Curr Opin Cardiol; 2008 Jul; 23(4):302-8. PubMed ID: 18520712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary use of glycoprotein IIb/IIIa inhibitors.
    Kristensen SD; Würtz M; Grove EL; De Caterina R; Huber K; Moliterno DJ; Neumann FJ
    Thromb Haemost; 2012 Feb; 107(2):215-24. PubMed ID: 22234385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.